Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is facing significant patent expirations in 2026-2028, which poses a risk to their revenue growth. However, the company has a strong pipeline with potential catalysts in various therapeutic areas, including oncology and obesity, and a focus on key growth drivers such as Padcev and Nurtec. With a moderate valuation at 9x forward P/E and a high dividend yield providing downside protection, Pfizer remains an attractive investment opportunity for income-focused investors.

Bears say

Pfizer is facing several headwinds that are contributing to the financial analyst's negative outlook. These include slower growth compared to its peers due to upcoming patent expirations for key drugs such as Vyndaqel and Eliquis, underwhelming performance of its obesity candidates compared to competitors, and inconsistent integration of sustainability considerations into its strategy. These factors, along with concerns about potential drug pricing reform and tariff policy changes, create uncertainty and limit the company's growth potential in the near and mid-term. While Pfizer's dividend is seen as safe, its high payout ratio suggests skepticism from the market on its ability to drive growth and make strategic investments.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.